Uncategorized
Kala Pharmaceuticals Reports Third Quarter 2018 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today reported financial results for the third quarter ended September 30, 2018. “We have made substantial progress over the past few months. In addition to receiving U.S. Food and Drug Administration (FDA) approval for INVELTYS™, we